Orexigen Therapeutics, Inc. (OTCMKTS:OREXQ) major shareholder Baupost Group Llc/Ma sold 1,546,339 shares of the company’s stock in a transaction dated Wednesday, October 31st. The shares were sold at an average price of $0.01, for a total value of $15,463.39. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.
Baupost Group Llc/Ma also recently made the following trade(s):
- On Thursday, October 25th, Baupost Group Llc/Ma sold 680,500 shares of Orexigen Therapeutics stock. The shares were sold at an average price of $0.01, for a total value of $6,805.00.
OREXQ stock opened at $0.01 on Friday. Orexigen Therapeutics, Inc. has a 1-year low of $0.00 and a 1-year high of $1.91.
Orexigen Therapeutics Company Profile
Orexigen Therapeutics, Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products primarily in the United States, Europe, and South Korea. It offers Contrave for the treatment of obesity. The company also offers Contrave under the Mysimba brand name. Orexigen Therapeutics, Inc was founded in 2002 and is headquartered in La Jolla, California.
Featured Story: Technical Analysis
Receive News & Ratings for Orexigen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orexigen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.